Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Baiyong Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-7447-9541; OpenAlex author ID A5112171317. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 6 papers · 2023: 4 papers · 2024: 1 paper · 2025: 4 papers

Papers 20

  1. Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. Co-author DOI 10.1016/j.xpro.2025.103635↗
  2. Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. Co-author DOI 10.1016/j.ymthe.2025.09.004↗
  3. Prevalence and clinical relavance of germline mutations in Chinese patients with pancreatic cancer. Co-author DOI 10.1186/s12964-025-02281-1↗
  4. Identification of a Novel Small Molecule STING Agonist Reshaping the Immunomicroenvironment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/ijbs.107837↗
  5. CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. Co-author DOI 10.1016/j.xcrm.2024.101692↗
  6. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… Co-author DOI 10.1007/s00262-023-03438-y↗
  7. A novel pyroptosis-associated lncRNA LINC01133 promotes pancreatic adenocarcinoma development via miR-30b-5p/SIRT1 axis. Last author DOI 10.1007/s13402-023-00818-5↗
  8. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Last author DOI 10.1097/js9.0000000000000264↗
  9. The value of 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance whole-body scans and local enhancement scans in the preoperative staging an… Co-author DOI 10.21037/qims-22-731↗
  10. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Co-author DOI 10.1002/ctm2.1126↗
  11. Oncological outcomes of robotic pancreatectomy in patients with pancreatic cancer who receive adjuvant chemotherapy: A propensity score-matched retrospective c… Last author DOI 10.1016/j.ijsu.2022.106801↗
  12. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-022-01338-9↗
  13. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. Last author DOI 10.1186/s13045-022-01348-7↗
  14. Identification of a lncRNA based signature for pancreatic cancer survival to predict immune landscape and potential therapeutic drugs. Last author DOI 10.3389/fgene.2022.973444↗
  15. Identification of EMT-related alternative splicing event of TMC7 to promote invasion and migration of pancreatic cancer. Last author DOI 10.3389/fimmu.2022.1089008↗
  16. Preoperative Plasma D-Dimer Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Radical Resection Last author DOI 10.21203/rs.3.rs-308863/v1↗
  17. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A. Co-author DOI 10.3892/ijo.2020.5120↗
  18. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  19. MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2016.12.167↗
  20. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Last author DOI 10.18632/oncotarget.7375↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chenghong Peng · 7 shared papers, 2016–2025 · strength 0.92
  2. Chenlei Wen · 7 shared papers, 2016–2025 · strength 0.89
  3. Da Fu · 4 shared papers, 2022–2025 · strength 0.69
  4. Xiaxing Deng · 5 shared papers, 2016–2023 · strength 0.67
  5. Lingxi Jiang · 4 shared papers, 2022–2025 · strength 0.65
  6. Berina Šabanović · 3 shared papers, 2024–2025 · strength 0.55
  7. Quan Zheng · 3 shared papers, 2024–2025 · strength 0.55
  8. Christopher Heeschen · 3 shared papers, 2024–2025 · strength 0.55
  9. Jiabin Jin · 3 shared papers, 2022–2025 · strength 0.55
  10. Yang Liu · 2 shared papers, 2025 · strength 0.47
  11. Weishen Wang · 2 shared papers, 2023 · strength 0.39
  12. Shuyu Zhai · 2 shared papers, 2022–2025 · strength 0.37
  13. Jiewei Lin · 2 shared papers, 2022–2023 · strength 0.36
  14. Yuanchi Weng · 2 shared papers, 2022 · strength 0.35
  15. Hao Chen · 3 shared papers, 2016–2023 · strength 0.35
  16. Xiaxing Deng · 2 shared papers, 2022 · strength 0.34
  17. Jiajia Tang · 2 shared papers, 2024–2025 · strength 0.33
  18. Elisabetta Fenocchio · 2 shared papers, 2024–2025 · strength 0.33
  19. Yaru Zhao · 2 shared papers, 2024–2025 · strength 0.33
  20. Qi Wang · 2 shared papers, 2024–2025 · strength 0.33
  21. Haoda Chen · 2 shared papers, 2021–2022 · strength 0.30
  22. Cheng Xiong · 2 shared papers, 2022–2023 · strength 0.29
  23. Lijie Han · 2 shared papers, 2022–2023 · strength 0.29
  24. Yongsheng Jiang · 2 shared papers, 2022–2023 · strength 0.29
  25. Youwei Zhu · 2 shared papers, 2022–2023 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.